Families with a glioblastoma diagnosis usually find three ways to get a dendritic-cell (DC) vaccine: paying a private clinic in Germany, enrolling in a clinical trial in the United States or United Kingdom, or joining a fee-based authorized program in China such as ours. None of the three is an approved medicine. This page sets out what each route is, who can get it, what it costs, what the evidence shows and what to watch out for, so you can ask the right questions wherever you go.
Figures about other providers come from their own publications, trial registries and public medical-travel listings as of October 2026 and are linked below. We run the China program described here, so read our column with that in mind; we have tried to apply the same standard of evidence to all three.
Medically reviewed by Prof. Youwen He, MD, PhD · Last updated 16 October 2026
A German private clinic is the fastest to access, but it adds an undefined tumor-lysate vaccine and contested hyperthermia to your standard care at the highest price per unit of evidence, with repeat visits for a year or more. A US or UK trial is free but hard to qualify for and may randomize you. The China program is the only route that designs the vaccine from sequencing of your own tumor, combines it with checkpoint blockade, and delivers surgery, chemoradiation and the vaccine as one hospital pathway in 12 to 14 weeks, with Phase I time-to-recurrence more than double the standard-care benchmark; as a complete pathway it is usually the least expensive of the paid options. No route is an approved medicine or guarantees an outcome.
| Germany: private DC clinics | US and UK: clinical trials (DCVax-L and others) | China: Tricision program | |
|---|---|---|---|
| The vaccine | Dendritic cells loaded with a crude lysate of the patient's tumor: an undefined mix of mostly normal self-proteins, with no selection of tumor-specific or neo-antigens. Some clinics add Newcastle disease virus injections and "modulated electrohyperthermia", a heating device whose benefit is contested. Needs enough of your own tumor tissue, collected and stored at surgery; if your hospital did not bank it, the vaccine may not be possible. | DCVax-L: autologous dendritic cells loaded with tumor lysate. Other trials use neoantigen- or peptide-pulsed dendritic cells; the design differs trial by trial. | Dendritic cells loaded with mRNA for antigens chosen from whole-exome and RNA sequencing of your tumor, including tumor-specific neoantigens, with triVac modification that raised T-cell responses about 15-fold in patient samples; combined with anti-PD-1 checkpoint blockade, poly I:C and low-dose cyclophosphamide. Sequencing works from small amounts of tissue, in many cases including archived pathology samples. |
| Regulatory status | Not an approved medicine. Given as an individual treatment attempt under German law; IOZK holds a manufacturing authorization for its vaccine. | DCVax-L is not approved anywhere. A UK marketing authorization application was filed in December 2023 and was still under review in October 2026. All other DC vaccines are investigational. | Not an approved drug. Authorized clinical use under China's Beidaihe national pilot framework with hospital oversight; the program is inspected and priced on file. A Phase II trial is registered (CTR20261465; NCT07715097). |
| How you get access | Self-referral to the clinic; you pay privately. Intermediaries advertise treatment starting within days of a records review. | Enroll in a trial if you meet its criteria. DCVax-L has no commercial or compassionate route open to the public. Trials are mostly limited to patients who can attend a US or UK center for the whole protocol. | Remote records review, then written acceptance by the multidisciplinary team. Fee-based; open to international patients. |
| Who qualifies | Decided by the clinic; broad, including recurrent disease, subject to performance status. | Strict and trial-specific: usually newly diagnosed GBM, enrollment at or before chemoradiation, age limits, Karnofsky 70 or above, no treatment outside the protocol. Recurrent GBM needs a separate trial. | Adults with newly diagnosed, post-operative or recurrent GBM; Karnofsky about 70 or above; tumor tissue available for sequencing; selected other solid tumors. |
| Timeline | Vaccine takes weeks to prepare; then repeated cycles of virus injections, hyperthermia sessions and vaccine boosts for a year or more, each requiring a trip to Cologne or a long stay. | Screening windows are tight. DCVax-L's Phase 3 protocol gave multiple doses over up to two years at the trial center. | About 12 to 14 weeks in China: assessment, surgery if indicated, sequencing and cell collection, manufacturing during chemoradiation, three doses about two weeks apart, then remote follow-up at home. |
| What you pay | Public medical-travel listings quote about €20,000 to €38,000 for the DC vaccination itself (2026). Surgery, chemoradiation, travel and stay are extra. | The trial drug and trial-related tests are free. Standard care is billed as usual; travel and living costs are yours. No price exists for DCVax-L because it is not sold. | Written quote after the records review, before any payment. The medical fee covers review, sequencing, vaccine manufacturing and hospital care; living packages are optional. The Survivin mRNA-LNP route costs roughly one-tenth of the cell-vaccine component. Insurance does not cover any of the three routes. |
| Evidence | Retrospective series from the clinic itself, in patients who could pay and travel. The only randomized trial the same lead investigator ran, HGG-2010 in Leuven, has not reported a positive result in a full publication, and the one completed European randomized DC-vaccine trial in GBM (Audencel) showed no survival benefit. Claims such as "one third cured" come from intermediaries, not from trials. | DCVax-L: Phase 3, 331 patients, median overall survival 19.3 months versus 16.5 months in external controls (JAMA Oncology 2023); the external-control design is debated. Other DC trials have no results yet. | Phase I (7 patients) plus an investigator study (13 GBM patients in total): median time to MRI recurrence 15.4 months versus about 6.9 months historical; all 7 Phase I patients alive and 5 recurrence-free in October 2026; first patient more than 9 years recurrence-free. No randomized trial; company-reported. |
| Value for money | You pay for the vaccine only; surgery, chemoradiation and hospital care are bought separately at German private rates, and travel repeats with each injection. | Free if you qualify, but you fund months near a US or UK center, and standard care is billed at local rates. No paid option exists. | One itemized quote covers review, sequencing, manufacturing, surgery where indicated, chemoradiation and hospital care, in a country where hospital costs are a fraction of US or German private rates. The Survivin mRNA-LNP option is the lowest-cost paid vaccine route of the three. Beijing Tiantan Hospital, ranked first in China for neurosurgery, is among the highest-volume neurosurgical centers in the world. |
| Watch-outs | An outpatient immunotherapy center, not a hospital: surgery, radiotherapy and emergencies happen elsewhere and coordination is yours. Ask what the price includes, whether your tissue is usable, and for the clinic's own published data rather than an intermediary's cure claims. | You may be randomized to the control arm; ask about crossover. Check whether you can stay near the center for the whole protocol. | A new program abroad with small patient numbers. Plan for the stay length, interpreting and family logistics. No outcome is guaranteed. |
All three routes require standard surgery, radiotherapy and temozolomide where indicated. None replaces them.
German private clinics, best known through the Immuno-Oncological Center Cologne (IOZK), make a dendritic-cell vaccine from a lysate of the patient's own tumor and give it as repeated outpatient injections. It is legal as an individual treatment attempt, quick to access and paid privately, with evidence limited to case series.
What it is. Monocytes from your blood are matured into dendritic cells and loaded with a lysate of your tumor tissue. The vaccine is made from a crude lysate: every protein in the sample, most of them normal self-proteins, with no step that identifies the mutations unique to your cancer. It therefore cannot be tuned to your tumor's IDH or MGMT status or to neoantigens. The IOZK protocol adds intravenous Newcastle disease virus and modulated electrohyperthermia, a radiofrequency heating device with little independent evidence.
Access and cost. You contact the clinic or an intermediary directly. Medical-travel listings in 2026 quote €20,000 to €38,000 for the vaccination itself; standard care, travel and accommodation are additional. Clinics usually ask for recent MRI, pathology, a performance-status assessment and enough frozen tumor tissue; without the tissue the vaccine may not be possible.
Evidence. Published work from IOZK consists of retrospective single-center series: for example, 50 selected adults with IDH-wildtype GBM and a median survival of 27 months, in patients who could pay, travel repeatedly and mostly had complete resections, against no control group. The lead investigator's own randomized, placebo-controlled trial in Leuven (HGG-2010) has not reported a positive result in a full publication, and Europe's completed randomized DC-vaccine trial in GBM (Audencel, 2018) showed no effect on survival. Intermediary pages advertising "one third cured" cite no trial.
Who it suits. Patients who want the shortest path to a DC vaccine, can fund it privately and can travel to Germany repeatedly or stay for the injection schedule.
In the US and UK, dendritic-cell vaccines for glioblastoma are available only inside clinical trials. DCVax-L, the most studied, completed a 331-patient Phase 3 trial and has a UK marketing application under review since December 2023, but it is not approved or sold anywhere. Trials are free, selective and location-bound.
DCVax-L. Northwest Biotherapeutics' lysate-loaded dendritic-cell vaccine. The Phase 3 trial (Liau et al., JAMA Oncology 2023) reported median overall survival of 19.3 months in newly diagnosed GBM against 16.5 months in external controls, and 15 percent alive at four years. Because the comparison used external rather than concurrent controls, the result is debated among neuro-oncologists. The company filed for UK marketing authorization in December 2023; the MHRA review was still open in October 2026. There is no way to buy DCVax-L.
Other trials. ClinicalTrials.gov lists DC-vaccine trials for newly diagnosed GBM such as DOC1021 (NCT06805305, Phase 2) and a neoantigen-pulsed DC vaccine with temozolomide (NCT07365280, Phase 2). Each has its own eligibility window, usually around the start of chemoradiation, and its own dosing schedule at the trial center.
Access and cost. The investigational vaccine and trial procedures are free; standard care is billed normally; travel and stay are at your expense. You must meet every inclusion criterion and may be randomized to the control arm. Most trials require that you be treated at the trial center for the whole protocol.
Who it suits. Newly diagnosed patients who are identified before chemoradiation, meet the criteria and can commit to a US or UK center for months. Recurrent patients need to search for recurrent-GBM trials specifically.
Our program gives a dendritic-cell vaccine loaded with mRNA for antigens chosen from sequencing of your own tumor, as three doses about two weeks apart within a 12-to-14-week stay, under hospital oversight in China's Beidaihe pilot zone. It is fee-based, open to international patients after a remote records review, and supported by Phase I data rather than a completed randomized trial.
What it is. Whole-exome and RNA sequencing of your tumor identify targets; our pipeline encodes them as mRNA with triVac antigen modification and loads them into your own dendritic cells in Tricision's GMP facility. The multidisciplinary team may combine the vaccine with anti-PD-1, poly I:C and low-dose cyclophosphamide. Standard surgery, radiotherapy and temozolomide continue as indicated. A lower-cost Survivin mRNA-LNP route exists for patients the team considers suitable.
Access and cost. You send records for a remote review; the multidisciplinary team's report and a written estimate follow in about a week, before any decision or payment. The medical fee covers review, sequencing, manufacturing and hospital care; living costs are separate and can be covered by optional packages. Insurance does not apply.
Evidence. In the Phase I cohort, median time to recurrence on MRI is 15.4 months at the current data cut against about 6.9 months with standard treatment alone; all 7 Phase I patients are alive and 5 recurrence-free as of October 2026; the first patient treated, whose case is published, is more than 9 years without recurrence. These are company-reported figures from a small group with short follow-up. A Phase II trial is registered (CTR20261465; NCT07715097). Full details are on our evidence section and science page.
Who it suits. Newly diagnosed, post-operative or recurrent GBM patients with Karnofsky about 70 or above and tumor tissue available, who can spend 12 to 14 weeks in China with a companion.
Three reasons, each with its limits stated: the complete pathway usually costs less than assembling the same care in Germany or the US; the hospitals involved are among the largest and most experienced neurosurgical centers in the world; and the vaccine is the only one of the three designed from sequencing of the patient's own tumor, with Phase I time-to-recurrence more than double the standard-care benchmark.
Cost. German clinics price the vaccine alone at about €20,000 to €38,000 on public listings; surgery, chemoradiation, hospital stays and repeated travel are bought separately at German private rates. In China, hospital care, surgery and chemoradiation cost a fraction of US or German private prices, so the one itemized quote you receive covers the whole pathway, not one component. The Survivin mRNA-LNP route, at roughly one-tenth of the cell-vaccine component, is the lowest-cost paid vaccine option among the three. We do not publish a list price because the quote depends on whether surgery is needed and what the multidisciplinary team plans; you receive it in writing before any decision.
Standard of care. A German immunotherapy center is an outpatient practice: your surgery, radiotherapy and any emergency happen in other institutions, and the coordination falls on you. Here, surgery, chemoradiation, vaccine manufacturing and the vaccine course are one pathway under one multidisciplinary team. Neurosurgery is provided with Beijing Tiantan Hospital, ranked first in China for neurosurgery and among the highest-volume neurosurgical centers in the world, with brain-tumor surgeons who operate on more glioma cases in a year than most Western centers see in several. Treatment is delivered in licensed hospitals inside a national pilot zone, inspected and with prices on file, and the vaccine is made on China's first GMP-grade mRNA production line under ISO 9001. China's cell-therapy and mRNA manufacturing capacity has grown into one of the largest in the world over the past decade, which is why trials from Western sponsors are now run there too.
Results. Only our route identifies the mutations unique to your tumor and encodes them as mRNA, with triVac modification that raised T-cell responses about 15-fold in patient samples, and only ours combines the vaccine with checkpoint blockade in one protocol. In the Phase I cohort, median time to recurrence on MRI is 15.4 months against about 6.9 months with standard treatment alone, every patient treated so far has passed the standard-care average, and the first patient treated is more than 9 years without recurrence in a peer-reviewed case report. We still do not claim to beat DCVax-L head to head: its 19.3-month figure is overall survival from a 331-patient trial, ours is time to recurrence from a small early cohort, and the populations differ. We show both so that you and your oncologist can weigh them. No route guarantees an outcome.
Whichever route you consider, ask for the same seven things in writing: regulatory basis, the exact vaccine design, published outcomes with patient numbers, eligibility criteria, the full timeline, an itemized cost, and what happens if the tumor progresses during treatment. A provider that cannot answer all seven is telling you something.
No. As of October 2026 DCVax-L is not approved in any country and is not sold. The UK marketing application filed in December 2023 remains under review. Access is only through clinical trials, which are currently limited.
A clinical trial, because the investigational vaccine is free, but only if you qualify and can live near the center. Among paid routes, German clinics publish third-party price ranges of about €20,000 to €38,000 for the vaccination alone; our program quotes in writing after review, and its Survivin mRNA-LNP option is roughly one-tenth the cost of the cell vaccine. Always compare what is included.
DCVax-L has the largest trial, a 331-patient Phase 3 with external controls. German clinic data are retrospective series. Our data are Phase I plus an investigator study in 13 patients. None of the three has a completed randomized controlled trial, so no route can promise an outcome.
All three routes are designed to be added to standard surgery, radiotherapy and temozolomide. The practical question is timing: trials usually require enrollment around the start of chemoradiation, while private clinics and our program can take post-operative and recurrent patients. Discuss timing with your home oncologist before committing.
Most newly-diagnosed trials exclude recurrent disease; you would need a recurrent-GBM trial. German clinics and our program accept recurrent patients subject to performance status and tissue availability. Expectations should be set accordingly: recurrent disease is harder to treat on every route.
Yes. The records review is remote and free of obligation, and the multidisciplinary team will say in writing if it thinks another route, or none, is more appropriate for a given case.
Prices and regulatory statuses of other providers change. We check this page quarterly and note the date at the top; tell us at ryanzhang@tricisionbio.com if something is out of date.